OFFICIAL PUBLICATION OF

by its subsidiary APPco

ACCC vs Pfizer case comes to a close

Sheshtyn Paola 26/10/2018

The High Court has dismissed the ACCC’s application for special leave to appeal in its case against Pfizer Australia over the sale of atorvastatin This month the Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment handed down by the Full Federal Court on 25 May 2018, following a longstanding case

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Funding secured for non-8CPA programs

Medschecks and Diabetes MedsCheck are included and funded under the 8CPA. The programs under the 8CPA will be undergoing a…

Anthony Tassone

Eli Lilly clarifies Mounjaro availability

One would think they could have made a commercial decision eith a needle maker to supply requisite number of needles…

Erin Threlfall

Funding secured for non-8CPA programs

This is a big step forward in securing the sustainability and viability of HMRs and RMMRs. Remember there is an…

Debbie Rigby

Funding secured for non-8CPA programs

So well done to the PSA for securing this funding. So important that these very valuable program finally gets looked…

Bente Hart

ACCC vs Pfizer case comes to a close

Previous A matter of life and death

Next 5 hidden pitfalls in ‘standard’ franchise agreements

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous A matter of life and death

Next 5 hidden pitfalls in ‘standard’ franchise agreements

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.